Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing - Zacks.com

MarketWatch

Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing Zacks.com This week there were the usual regulatory and pipeline updates from the biotech sector. Juno (JUNO - Analyst Report) , a company focused on immuno-oncology treatments, was in the news with the FDA first placing a clinical hold on a pivotal study and ... Biosimilar to Humira Recommended by FDA PanelMedscape FDA panel backs Amgen's Humira copy, but don't expect to see it anytime soonFierceBiotech Amgen Biosimilar Gets Thumbs-Up From FDA PanelWall Street Journal Reuters -Bloomberg -Regulatory Focus -PR Newswire (press release) all 74 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE2bO-1rm3PZEg0XJRwKNgCM8b70g&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779155682280&ei=-5aGV8CZNoG9pwe6u5GACQ&url=https://www.zacks.com/stock/news/223352/biotech-stock-roundup-juno-in-and-out-of-clinical-hold-amgen-biosimilar-gets-panel-backing
via IFTTT